Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.

Abstract:

:The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to the time needed to achieve complete viral suppression. A total of 325 HBeAg-positive CHB patients with high viral load who were recently started on antiviral therapy with entecavir or tenofovir were included. The enrolled patients were divided into 2 groups with 4 separate criteria based on the time needed to achieve complete viral suppression: within 1, 2, 3 or 4 years of therapy initiation. The outcomes were development of HCC and cirrhosis. The cumulative incidence of HCC was significantly higher in patients failing complete viral suppression within 1 year (hazard ratio (HR), 4.54; 95% confidence interval (CI), 1.03-19.93; P = .045) or 2 years (HR, 3.38; 95% CI, 1.24-9.23; P = .018), than patients who achieved complete viral suppression within 1 or 2 years, respectively. Cumulative incidence of cirrhosis was also significantly higher in patients failing suppression within 1 year (HR, 1.95; 95% CI, 1.04-3.66; P = .037) or 2 years (HR, 2.44; 95% CI, 1.41-4.22; P = .001). When the time for achieving viral suppression exceeded 2 years, the cumulative incidence of HCC or cirrhosis was not different regardless of viral suppression. Complete hepatitis B virus suppression within 2 years of antiviral therapy initiation is associated with risk reduction in HCC or cirrhosis development.

journal_name

J Viral Hepat

authors

Nam JY,Chang Y,Cho H,Kang SH,Cho YY,Cho EJ,Lee JH,Yu SJ,Yoon JH,Kim YJ

doi

10.1111/jvh.12838

subject

Has Abstract

pub_date

2018-05-01 00:00:00

pages

552-560

issue

5

eissn

1352-0504

issn

1365-2893

journal_volume

25

pub_type

杂志文章
  • Therapy of chronic hepatitis B: current challenges and opportunities.

    abstract::Better understanding of hepatitis B virus (HBV) replication, natural history and the immunopathogenesis of chronic hepatitis B, together with the introduction of effective agents with different mechanisms of action are the basis for better therapeutic strategies against chronic hepatitis B. Among currently available d...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2002.00388.x

    authors: Liaw YF

    更新日期:2002-11-01 00:00:00

  • Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus.

    abstract::To evaluate, among 70 hepatitis C virus (HCV)-monoinfected and 36 human immunodeficiency virus (HIV)-coinfected naïve patients with genotypes 1/4 receiving weight-adjusted pegylated interferon-alpha-2b/ribavirin, viral kinetics and the feasibility to predict treatment failure measuring early HCV-RNA decreases. HCV-RNA...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00710.x

    authors: Moreno A,Bárcena R,García-Garzón S,Moreno L,Quereda C,Muriel A,Zamora J,Mateos ML,Pérez-Elías MJ,Antela A,Diz S,Moreno A,Moreno S

    更新日期:2006-07-01 00:00:00

  • Immune modulation by the hepatitis C virus core protein.

    abstract::Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral pers...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12675

    authors: Fernández-Ponce C,Dominguez-Villar M,Muñoz-Miranda JP,Arbulo-Echevarria MM,Litrán R,Aguado E,García-Cozar F

    更新日期:2017-05-01 00:00:00

  • Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.

    abstract::The efficacy of lamivudine re-treatment in chronic hepatitis B (CHB) patients who relapse after HBeAg seroconversion with lamivudine has not been investigated. The aim of this study was to evaluate the efficacy of lamivudine re-treatment in relapsed patients. Among 192 patients who had achieved HBeAg seroconversion wi...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2005.00606.x

    authors: Shin JW,Park NH,Park JH,Park JH,Jeong ID,Bang SJ,Joo KR,Kim DH

    更新日期:2005-07-01 00:00:00

  • Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.

    abstract::We aimed to compare the evolution of estimated glomerular filtration rate (eGFR) in HIV-, HIV-HBV- and HBV-infected patients treated with tenofovir disoproxil fumarate (TDF). Three groups of patients receiving TDF > 12 months were recruited: 194 HIV-infected patients, 85 HIV-HBV-coinfected patients and 50 HBV-infected...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12088

    authors: Pradat P,Le Pogam MA,Okon JB,Trolliet P,Miailhes P,Brochier C,Maynard M,Bailly F,Zoulim F,Cotte L

    更新日期:2013-09-01 00:00:00

  • Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial.

    abstract::Better convenience and tolerability and sustained therapeutic concentrations might improve interferon (IFN) treatment for chronic hepatitis C virus (HCV) infection. In an open-label, randomized study, controlled release free (chemically unmodified) recombinant human IFN-α(2b) in poly(ether-ester) microspheres (CR-rhIF...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2010.01298.x

    authors: Dzyublyk I,Yegorova T,Moroz L,Popovych O,Zaytsev I,Miroshnichenko V,Kromminga A,Wilkes MM,van Hoogdalem EJ,Humphries JE

    更新日期:2011-04-01 00:00:00

  • Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.

    abstract::Assessment and treatment for hepatitis C virus (HCV) in the community remains low. We evaluated factors associated with HCV specialist assessment and treatment in a cross-sectional study to evaluate treatment considerations in a sample of 634 participants with self-reported HCV infection in New South Wales, Australia....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01370.x

    authors: Grebely J,Bryant J,Hull P,Hopwood M,Lavis Y,Dore GJ,Treloar C

    更新日期:2011-04-01 00:00:00

  • Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study.

    abstract::This study examined the association between chronic HBV or HCV infection and the risk of extrahepatic cancers. A total of 537 103 adults aged ≥20 years without history of cancer were identified from the Korean National Health Insurance Service-National Sample Cohort between 2003 and 2013. The difference in cancer inci...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13304

    authors: Hong CY,Sinn DH,Kang D,Paik SW,Guallar E,Cho J,Gwak GY

    更新日期:2020-09-01 00:00:00

  • Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.

    abstract::Chronic hepatitis B (CHB) is characterized by an impaired immune response to hepatitis B virus. Among the nucleos(t)ides used in CHB treatment, telbivudine is associated with the highest rates of hepatitis B e antigen (HBeAg) seroconversion rates, which are similar to those observed with pegylated interferon (PegIFN)....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12059

    authors: Wang GQ,Ding YP,Dong YH

    更新日期:2013-04-01 00:00:00

  • How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?

    abstract::Chronic hepatitis C represents a major cause of progressive liver disease that can eventually evolve into cirrhosis and its end-stage complications. Formation and accumulation of fibrosis in the liver is the common pathway that leads to evolutive liver disease. Precise staging of liver fibrosis is essential for patien...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01518.x

    authors: Sebastiani G,Alberti A

    更新日期:2012-01-01 00:00:00

  • Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.

    abstract:SUMMARY:Hepatitis C virus (HCV) genotypes 1 and 4 respond less well to pegylated interferon (pegIFN) plus ribavirin (RBV) therapy. For this reason most studies merge these two genotypes when assessing virological response. However, in most trials the HCV genotype 4 population is rather small, and conclusions are mainly...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2008.01015.x

    authors: Martín-Carbonero L,Puoti M,García-Samaniego J,De Luca A,Losada E,Quinzan G,Bruno R,Mariño A,González M,Núñez M,Soriano V

    更新日期:2008-10-01 00:00:00

  • Prevalence and impact of hepatitis B virus infection in ovarian cancer patients in an endemic area-A retrospective cohort study.

    abstract::Hepatitis B virus (HBV) infection is associated with many extrahepatic malignancies, but its association with and impact on ovarian cancer has not been examined. We therefore examined the prevalence of HBV infection among women with primary ovarian carcinoma in an endemic area, and whether this impacts the presentatio...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13250

    authors: Wong L,Cheung TH,Yim SF,Lao TT

    更新日期:2020-05-01 00:00:00

  • Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.

    abstract::The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German He...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13280

    authors: Knop V,Mauss S,Goeser T,Geier A,Zimmermann T,Herzer K,Postel N,Friedrich-Rust M,Hofmann WP,German Hepatitis C-Registry.

    更新日期:2020-07-01 00:00:00

  • Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B.

    abstract::Quantitative serology for hepatitis B surface antigen (HBsAg) is a new candidate marker for prediction of clinical outcome. The aim of this study was to investigate the clinical significance of quantifying HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424 patients who tested positive for HBsAg a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01486.x

    authors: Togo S,Arai M,Tawada A,Chiba T,Kanda T,Fujiwara K,Imazeki F,Yokosuka O

    更新日期:2011-10-01 00:00:00

  • Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action.

    abstract::Although hepatitis C (HCV) is associated with diabetes, few studies have examined pre-diabetes in this population. We aimed to evaluate factors associated with pre-diabetes in HCV-infected patients, including direct measurement of insulin action. Ninety-seven non-cirrhotic, non-diabetic and HCV-infected patients under...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01568.x

    authors: Mukhtar NA,Ayala C,Maher JJ,Khalili M

    更新日期:2012-07-01 00:00:00

  • Different responses of rat liver adenosine metabolizing enzymes during in vivo and in vitro treatment with interferon-alpha 2b.

    abstract::Interferon-alpha 2b (IFN-alpha 2b) can exert antiproliferative activity in both normal and malignant liver tissue. To study mechanisms of its antiproliferative action, the activity of the enzymes of adenosine metabolism were investigated. We studied 5'-nucleotidase (an adenosine-producing enzyme) and adenosine deamina...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00117.x

    authors: Kocić G,Kocić R,Vlahović P,Pavlović D,Jevtović T

    更新日期:1998-09-01 00:00:00

  • Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus.

    abstract::Hepatitis C virus (HCV) is a human hepatotropic virus, but many hepatoma cell lines are not permissive to this virus. In a previous study, we observed that SNU-182, SNU-398 and SNU-449 hepatoma cell lines were nonpermissive to HCV. To understand the nonpermissivity, we evaluated the ability of each cell line to suppor...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12767

    authors: Fournier C,Hoffmann TW,Morel V,Descamps V,Dubuisson J,Brochot E,Francois C,Duverlie G,Castelain S,Helle F

    更新日期:2018-01-01 00:00:00

  • Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells.

    abstract::Dendritic cells (DCs) in chronic hepatitis C patients display impaired function, although the details remain unclear. To investigate the hepatitis C virus (HCV) protein that has the most impact on DC function, we compared five recombinant proteins and seven HCV protein genes in modulating DC phenotype and function. Im...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01213.x

    authors: Takaki A,Tatsukawa M,Iwasaki Y,Koike K,Noguchi Y,Shiraha H,Sakaguchi K,Nakayama E,Yamamoto K

    更新日期:2010-08-01 00:00:00

  • Augmentation of hepatitis C virus-specific immunity and sustained virologic response.

    abstract::Treatment for chronic hepatitis C virus (HCV) infection has rapidly evolved into interferon-free directly acting antiviral regimens (DAA) that result in high sustained virologic response. DAAs primarily work by suppressing HCV replication and rely less on the immune system than interferon-based therapies. However, it ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12702

    authors: Shrivastava S,Wilson E,Poonia B,Tang L,Osinusi A,Kohli A,Kottilil S

    更新日期:2017-09-01 00:00:00

  • Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

    abstract::This open label study was initiated to assess the safety and efficacy of lymphoblastoid interferon-alpha (IFN-alpha) and thymosin alpha 1 (T alpha 1) in the treatment of 11 patients with chronic hepatitis B, who had failed to respond to standard IFN-alpha 2b therapy, and in four interferon naive patients. These fiftee...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.1996.tb00094.x

    authors: Rasi G,Mutchnick MG,Di Virgilio D,Sinibaldi-Vallebona P,Pierimarchi P,Colella F,Favalli C,Garaci E

    更新日期:1996-07-01 00:00:00

  • Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis.

    abstract::Clinical and experimental studies have demonstrated that connective-tissue growth factor (CTGF) expression is increased in fibrotic human liver and experimental animal models of liver fibrogenesis. CTGF has been linked to transforming growth factor-beta (TGF-beta) pathways in fibroproliferative diseases and specific p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01110.x

    authors: Kovalenko E,Tacke F,Gressner OA,Zimmermann HW,Lahme B,Janetzko A,Wiederholt T,Berg T,Müller T,Trautwein C,Gressner AM,Weiskirchen R

    更新日期:2009-09-01 00:00:00

  • Hepatitis E virus infection among animals in northern India: an unlikely source of human disease.

    abstract::Hepatitis E virus (HEV) is a major cause of acute hepatitis in many developing countries. Based on data from nonendemic regions, an animal reservoir of HEV has been proposed; however, data from HEV-endemic regions are limited. We tested sera from 200 pigs, 98 chickens, 86 goats, 58 sheep and 30 buffaloes for anti-HEV ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00815.x

    authors: Shukla P,Chauhan UK,Naik S,Anderson D,Aggarwal R

    更新日期:2007-05-01 00:00:00

  • Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.

    abstract::Neumann et al. [1] developed a widely used model for the analysis of hepatitis C virus (HCV) dynamics after the initiation of interferon therapy that assumes the effectiveness of therapy in blocking virion production, epsilon, is constant. However, with pegylated interferon alpha-2b (PEG-IFN) given weekly, there are s...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00954.x

    authors: Shudo E,Ribeiro RM,Perelson AS

    更新日期:2008-05-01 00:00:00

  • Natural history of serum HBV-RNA in chronic HBV infection.

    abstract::Virus-like particles encapsulating HBV-RNA represent a serum biomarker for assessing viral replication activity in clinical practice. However, baseline levels of serum HBV-RNA and their associations with viral replicative intermediates and liver disease in phases of chronic hepatitis B remain unknown. In this cross-se...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12908

    authors: Wang J,Yu Y,Li G,Shen C,Li J,Chen S,Zhang X,Zhu M,Zheng J,Song Z,Wu J,Shao L,Meng Z,Wang X,Huang Y,Zhang J,Qiu C,Zhang W

    更新日期:2018-09-01 00:00:00

  • Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.

    abstract::One hundred and thirty-one post-liver transplantation patients with chronic hepatitis B and failing lamivudine therapy with detectable serum hepatitis B virus (HBV) deoxyribonucleic acid by hybridization assays or > or =1 x 10(6) copies/mL by polymerase chain reaction, and elevated alanine transaminase levels despite ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00578.x

    authors: Westland CE,Yang H,Delaney WE 4th,Wulfsohn M,Lama N,Gibbs CS,Miller MD,Fry J,Brosgart CL,Schiff ER,Xiong S

    更新日期:2005-01-01 00:00:00

  • Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.

    abstract::Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three patients with cirrhosis (n=52) or fibrosing cholestatic hepatiti...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12712

    authors: Vukotic R,Conti F,Fagiuoli S,Morelli MC,Pasulo L,Colpani M,Foschi FG,Berardi S,Pianta P,Mangano M,Donato MF,Malinverno F,Monico S,Tamè M,Mazzella G,Belli LS,Viganò R,Carrai P,Burra P,Russo FP,Lenci I,Toniutto P

    更新日期:2017-10-01 00:00:00

  • Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.

    abstract::In this study, a comprehensive methodology for modelling the hepatitis C virus (HCV) epidemic is proposed to predict the future disease burden and assess whether the recent decline in the incidence of HCV may affect the future occurrence of cirrhosis and hepatocellular carcinoma (HCC) cases. Using the prevalence of HC...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00517.x

    authors: Sypsa V,Touloumi G,Tassopoulos NC,Ketikoglou I,Vafiadis I,Hatzis G,Tsantoulas D,Akriviadis E,Delladetsima J,Demonakou M,Hatzakis A

    更新日期:2004-07-01 00:00:00

  • Role of nitric oxide synthase genes in hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) is the most common cause of endemic and epidemic acute hepatitis. A correlation between iNOS, eNOS polymorphisms, levels and severity of disease has been reported, and here, we examined the role of iNOS and eNOS gene polymorphisms and their levels in HEV-related acute viral hepatitis and acute ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12186

    authors: Hazam RK,Deka M,Kar P

    更新日期:2014-01-01 00:00:00

  • Susceptibility to active decompensated cirrhosis is associated with polymorphisms of intercellular adhesion molecule-1 (ICAM-1) in chronic HBV carriers.

    abstract::Intercellular adhesion molecule-1 (ICAM-1) plays an important role in the pathogenesis of viral hepatitis B. Several inflammatory diseases are associated with distinct polymorphisms of the ICAM-1 gene. The aims of this study were to analyse the association of ICAM-1 polymorphisms G241R and K469E with susceptibility to...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00931.x

    authors: Zhang XQ,Hong XJ,Bai XJ

    更新日期:2008-03-01 00:00:00

  • Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers.

    abstract::In 1996, a combined vaccine against both hepatitis A and B was licensed and commercialized and has been recommended for healthcare personnel in Belgium. This study compares the immunogenicity against hepatitis B virus (HBV) and safety of two vaccination schedules (0-1-12 months and 0-1-6 months) with this vaccine. Thi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2010.01365.x

    authors: De Schryver A,Verstrepen K,Vandersmissen L,Vandermeeren N,Vernaillen I,Vranckx R,Van Damme P,van Sprundel M

    更新日期:2011-04-01 00:00:00